Drugs Related Topics 
Outsourcing Pharma
APRIL 5, 2032
The Australian biotechnology company has been granted ODD status from the agency for Veyonda, a therapy intended for the treatment of soft-tissue sarcoma. Markets & Regulations
Pharma Mirror
OCTOBER 4, 2021
Open source drug discovery was proposed in the past in connection with third-world diseases like tuberculosis and malaria, but it is in the context of first-world indications where it is needed most. The post Open Source “Wikipedia” for Drug Discovery appeared first on Pharma Mirror Magazine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
OCTOBER 12, 2021
According to the KFF poll “ most adults – across partisans – don’t believe high drug prices are needed for drug companies to invest in new research instead agreeing that “even if U.S. The post Pharma losing the battle over drug prices.
Pharma Mirror
DECEMBER 16, 2022
While these researchers rose to the occasion by discovering drugs faster than ever before, variants continue to challenge the world in addressing COVID-19. New innovations in computer-aided drug discovery tools could dramatically accelerate the study of new variants.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
Pharma Phorum
JANUARY 12, 2023
As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Ben Hargreaves speaks to an expert in the area to learn how drug diversion occurs, and how it can be countered.
Bio Pharma Dive
MARCH 18, 2023
The eagerly anticipated results from a Phase 2 study in psoriasis show why the pharma paid $4 billion to buy the drug from startup Nimbus Therapeutics last year
Bio Pharma Dive
MARCH 17, 2023
The combination drug didn’t help patients any more than chemotherapy, but Merck will continue the trial to test it together with chemo
Bio Pharma Dive
JANUARY 11, 2023
The agency will kick off discussions on how it will negotiate Medicare drug prices in the spring and publish a list of the first 10 drugs selected by Sept.
World of DTC Marketing
JANUARY 28, 2022
When drug makers like Xtandi’s manufacturer, Astellas Pharma, price gouge sick Americans, the U.S. The post Drug company profiteering. A cancer medication called Xtandi costs $189,800 per year and was developed with taxpayer dollars. The U.S.
World of DTC Marketing
JULY 13, 2021
SUMMARY: The FDA has many puzzled as to why they approve some drugs with questionable data and ask for more data on other drugs. The FDA approves drugs on the potential to save a life, the cost of the drugs is never considered in the process.
Bio Pharma Dive
MARCH 7, 2023
Its most advanced drug is already in early-stage human testing Rapport Therapeutics aims to find new so-called receptor-associated proteins that could serve as targets for neurological disease medicines.
Bio Pharma Dive
MARCH 7, 2023
As many as a third of FDA-approved drugs target GPCRs in some fashion, with uses ranging from treating cancer to pain. But biotech startups say there is still room to develop more
Bio Pharma Dive
MARCH 13, 2023
The acquisition would give Pfizer control of a top-selling lymphoma drug and a pipeline of medicines that have made the Seattle-based company one of the sector’s most valuable biotechs
Bio Pharma Dive
MARCH 24, 2023
PureTech Health will sell some of its royalty interest in Karuna’s drug, known as KarXT, after its second successful late-phase trial this week
Bio Pharma Dive
FEBRUARY 14, 2023
Through social media, virtual meetings and mentorship programs, a growing group of entrepreneurs is looking for new ways to build drug companies
Drug Patent Watch
MARCH 21, 2023
Annual Drug Patent Expirations for NUZYRA Nuzyra is a drug marketed by Paratek Pharms Inc and is included in two NDAs. There are ten… The post New patent for Paratek Pharms drug NUZYRA appeared first on DrugPatentWatch - Make Better Decisions.
World of DTC Marketing
JULY 17, 2022
And the Covid-19 pandemic only underscored that obesity puts people at greater risk for infectious disease but are new weight loss drugs the answer? Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. As I See It Weight Loss Drugs
World of DTC Marketing
SEPTEMBER 7, 2021
While it’s true, the drug industry developed COVID vaccines; the government spent billions on research pre-pandemic and $18 billion more on trials, production, and purchase. Drug corps are reaping record profits. Drug companies should prepare for this scenario.
Bio Pharma Dive
FEBRUARY 28, 2023
The biotech said the FDA was unconvinced by available study evidence and asked for data from an additional clinical trial, which the company currently does not plan to run
Bio Pharma Dive
NOVEMBER 28, 2022
The company will cut its R&D workforce by 75% and discontinue development of its experimental lung cancer drug poziotinib
Bio Pharma Dive
MARCH 14, 2023
Responding to policy changes and pressure over high drug costs, the pharma is reducing the sticker price of four branded diabetes medicines by up to 75
Bio Pharma Dive
MARCH 20, 2023
The results add to a growing body of evidence that Karuna’s drug, known as KarXT, could be a valuable new option for patients living with the brain disorder
Bio Pharma Dive
DECEMBER 22, 2022
The pharma will pay the Chinese drugmaker $175 million for access to seven preclinical antibody-drug conjugates, deepening ties established this year
Pharmaceutical Technology
DECEMBER 22, 2022
The Drug Enforcement Administration (DEA) recently announced that it had seized 10,000 pounds of illicit fentanyl in 2022 and pointed out that this volume represented enough fentanyl to kill every American. A lethal drug that creates its own demand.
Bio Pharma Dive
JANUARY 30, 2023
The agency’s clearance of Jaypirca gives Lilly another win from its Loxo buyout, while Menarini Group’s bet on Radius Health’s oral SERD has now paid off with Orserdu’s OK
Drug Patent Watch
MARCH 4, 2023
This chart shows the drugs with the most patents in Ukraine. The post Which pharmaceutical drugs have the most drug patents in Ukraine? Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…
BioPharma Reporter
FEBRUARY 20, 2023
The partners will collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye. Drug Delivery
World of DTC Marketing
DECEMBER 10, 2020
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices
Bio Pharma Dive
SEPTEMBER 30, 2022
The biotechnology startup will part with its lead drug candidate, an anti-inflammatory small molecule, in Novo Nordisk’s bet on inflammasome treatments
Bio Pharma Dive
MARCH 9, 2023
Prior trial failures hadn’t halted testing of solanezumab, once Lilly’s top Alzheimer’s drug candidate. But its final study defeat may help scientists better understand how to target the brain disease
World of DTC Marketing
FEBRUARY 25, 2022
billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019. Food and Drug Administration approval for the non-Hodgkin lymphoma drug by a Dec.
Drug Patent Watch
MARCH 4, 2023
Annual Drug Patent Expirations for ORKAMBI Orkambi is a drug marketed by Vertex Pharms Inc and is included in two NDAs. There are twenty… The post New patent for Vertex Pharms drug ORKAMBI appeared first on DrugPatentWatch - Make Better Decisions.
Bio Pharma Dive
OCTOBER 10, 2022
By taking advantage of pre-filed DMFs, researchers benefit from the value, time savings and reduced complexities of having someone else do the heavy lifting for key components of the final drug product
Bio Pharma Dive
DECEMBER 13, 2022
The Japanese pharma is paying $4 billion upfront, and potentially $2 billion more, for a medicine Nimbus claims can top Bristol Myers’ recently approved psoriasis drug Sotyktu
Bio Pharma Dive
NOVEMBER 9, 2022
The biotech will sell its royalty interest in a heart disease drug Amgen is developing for $250 million, extending its operating runway by several quarters
Bio Pharma Dive
DECEMBER 1, 2022
The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing
Drug Patent Watch
FEBRUARY 27, 2023
Annual Drug Patent Expirations for XHANCE Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are thirteen… The post New patent for Optinose Us drug XHANCE appeared first on DrugPatentWatch - Make Better Decisions.
Bio Pharma Dive
DECEMBER 21, 2022
The pharma dosed the first patient in a Phase 2 study testing a treatment it hopes could compete with closely-watched weight-loss drugs from Lilly, Novo Nordisk and Amgen
Outsourcing Pharma
JANUARY 12, 2023
Drug DeliveryBiogen partners with Alcyone to gain access to ThecaFlex, which is able to deliver therapies into the intrathecal space.
Bio Pharma Dive
FEBRUARY 2, 2023
Though Goldfinch Bio focused on kidney diseases, Karuna believes its experimental drugs may have potential treating psychiatric and neurological conditions
World of DTC Marketing
OCTOBER 6, 2020
This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials.
World of DTC Marketing
MARCH 23, 2021
SUMMARY: Democratic lawmakers are weighing whether to include drug pricing measures that could extract tens of billions of dollars from the industry. We’re just not sure when,” said one drug industry lobbying source. The drug industry has had a large target on its back for a long time.
Expert insights. Personalized for you.
52 
Let's personalize your content